Autek China Inc. (China)

Autek China Inc. is a high-tech enterprise specializing in eye health and myopia prevention and control technology and services. It was founded in 2000 by Dr. Tao Yuequn, an engineering Ph.D. who studied in the United States. The company is headquartered in Hefei High-tech Development Zone, covering an area of 73 acres with a building area of 90,000 square meters. Autek China Inc. has approximately 350 subsidiaries and a total of around 2,900 employees, including nearly 400 at the headquarters. In 2022, the company's main business revenue was approximately 1.525 billion yuan, with a net profit of about 624 million yuan and a tax contribution of over 220 million yuan. Autek China Inc. was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in January 2017, becoming the first listed ophthalmic technology company in China. It ranked among the top ten medical device production listed companies in China in 2021 and is the leading ophthalmic company in the country. It is also one of the top ten listed companies in Anhui Province in terms of market value and one of the top 50 private enterprises in terms of tax contribution in Anhui Province in 2022 (ranked 38th). Additionally, it is recognized as one of the 100 "Excellent Private Enterprises in Anhui Province" awarded by the Anhui Provincial Party Committee and Government in 2021. Autek China Inc.'s business includes two main sectors: ophthalmic and optometric medical devices (products) and medical services. In terms of products, its main products are rigid contact lenses, such as corneal shaping lenses, and supporting care products. It is currently the only domestically listed company engaged in the research and development and production of rigid contact lenses and is also a globally significant company in the research and development and production of corneal shaping lenses. Corneal shaping lenses are special rigid contact lenses used to correct myopia. They are worn during sleep and removed upon waking, allowing for clear vision during the day and slowing down the progression of myopia. They are included in the "Myopia Prevention and Control Guidelines" issued by the National Health Commission in June 2018 and have been recognized by ophthalmic experts and users. The company's products are characterized by intelligence and personalization and have entered more than 1,500 well-known medical institutions nationwide, except for Tibet. As of the end of March 2022, the cumulative number of users is nearly 2 million, and DreamVision and Mengdaiwei have become well-known brands in this category. Wan Lijun, Chairman of the National Federation of Returned Overseas Chinese, and Jiao Hong, Director of the National Medical Products Administration, have visited the company for research and guidance. In addition to rigid contact lens products, the company is expanding its product and technology scope through independent research and development, commissioned development, cooperative development, investment and acquisition, and industrial funds. It has invested in more than 30 medical and health companies, including Guangzhou Weishi Bo, Hangzhou Mule, Anhui Boao, Anhui Ouwu, Shenzhen Kangkang, Guangzhou Shiming, Jingze Biology, Dijia Medical, Xingmou Biology, Jili Technology, Dingya Pharmaceutical and Chemical, Ruiying Medical, and Huiding Optics. With the support of the High-tech Zone and the Provincial Overseas Chinese Office, the company has established the "Qiaomengyuan Medical Device Innovation Base" to provide trial production platforms, clinical trials and registration application guidance, funding, and sales channel support to incubate new products and reserve power for future development. In terms of medical and optometric technology services, as of the first quarter of 2022, in addition to the main hospital in Hefei, Kangshi Eye Hospital chain institutions currently include 8 ophthalmic hospitals in Bengbu, Lu'an, Xuancheng, Ma'anshan, Shangrao, Panjin, Laizhou, and Xi'an, and have stakes in 4 ophthalmic hospitals in Langxi, Ningguo, Guangde, and Chengdu. At the same time, the company has established dozens of ophthalmic clinics and outpatient departments and over 200 eye and optometry centers nationwide. The company is increasing and accelerating its investment layout in the medical service field, aiming to establish a nationwide eye health and myopia prevention and control service network.